HOME >> BIOLOGY >> NEWS
Inhibition of insulin-like growth factor receptor-1 as promising anticancer therapeutic

Scientists report that an unlikely molecule has emerged as an attractive target for development of therapeutics aimed at a diverse spectrum of tumors, including some malignancies that are resistant to conventional therapies. Two studies published online in Cancer Cell demonstrate that the insulin-like growth factor 1 receptor (IGF-1R) is required for the survival of tumor cells and provide direct evidence that inhibition of IGF-R1 using selective small molecules represents a novel potential anticancer treatment.

Extensive studies have suggested that IGF-1R plays a role in the development of human cancers. IGF-1R is present in a broad range of tumor types including multiple myeloma, lymphoma, leukemia, and breast, lung, prostate, and colon cancers. However, IGF-1R has not been viewed as a likely target for cancer therapeutics because many normal cells also contain the protein. Research scientists from Dana-Farber Cancer Institute in Boston and Novartis Institutes for Biomedical Research Basel demonstrate that IGF-1R inhibition using a variety of methods had potent antitumor effects against many types of cancer cells grown in the laboratory, including cells that are resistant to conventional cancer therapeutics.

Molecular analyses demonstrated that IGF-1R inhibition impacts multiple intracellular signals related to cell proliferation or tumor development and provides possible mechanisms to explain how IGF-1R inhibition can make tumor cells more sensitive to conventional chemotherapy or other anticancer agents. Perhaps most significantly, IGF-1R suppresses tumor growth, prolongs survival, and enhances the antitumor effect of chemotherapy in clinically relevant mouse models of multiple myeloma and other hematological malignancies. The researchers also identify two small molecules that are selective inhibitors of IGF-1R and are active anticancer agents against tumors that contain IGF-1R. These small molecules represent highly attractive potential therapeu
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
26-Feb-2004


Page: 1 2

Related biology news :

1. Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice
2. Inhibition of Borrelia burgdorferi protein may reduce Lyme disease transmission
3. Inhibition Of A Novel Gene Involved In Phosphorylating Starch In TransgenicPotato Tubers Leads To The Repression Of Cold Induced Sweetening
4. Competitive Inhibition May Enhance Safety Of Minimally Processed Fruits And Vegetables
5. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
6. New Arizona State center brings science to policy on issues of water resources and urban growth
7. Researchers identify protein promoting vascular tumor growth
8. IBD (Crohns, Colitis) joins cancer, inflammatory diseases in associated blood vessel growth
9. Growth hormone and IBD: Reduction of intestinal inflammation, promotion of growth
10. Extreme stretch-growth of axons
11. Diabodies act as guided missiles targeted to mammary tumor growth

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/22/2020)... ... January 21, 2020 , ... ... validation strategies, supporting global regulatory applications, and executing global clinical trial operations. ... Journal as a fastest growing company, and ISO 9001:2015 certification with the ...
(Date:1/8/2020)... ... January 08, 2020 , ... ... offering complimentary overnight shipping to its nationwide practice network partners. Not only ... due to volume in its Network the biologics themselves are less expensive. , ...
(Date:1/7/2020)... ... 2020 , ... Myant Inc. , the pioneers in Textile Computing™, will ... life its vision of a world where textile-based interfaces knitted into everyday objects form ... and the physical IoT-enabled environment. The experience at Myant’s booth will challenge visitors to ...
Breaking Biology News(10 mins):
(Date:1/24/2020)... ... January 24, 2020 , ... ... RedySmart™ mass flow meters and controllers ideal for BioPharm OEMS. Sierra ... to antiquated rotameters. These thermal instruments employ high-precision MEMS (Micro-Electro Mechanical Systems) technology ...
(Date:1/22/2020)... ... January 21, 2020 , ... COBO Technologies and Cardea Bio ... partners have agreed to co-develop and market a portfolio of CRISPR QC products ... Over the longer-term, the parties aim to develop a COBO branded QC device ...
(Date:1/10/2020)... ... January 09, 2020 , ... GenScript Biotech Corp., ... Biotech Global Forum on Jan. 14 in San Francisco, coinciding with the JP ... and the Booming China Market," will feature gene and cell therapy leaders in ...
(Date:1/7/2020)... ... ... Vuja De Sciences (“Vuja De”), a biotechnology startup dedicated to developing cancer metastasis ... DVM, PhD, DACVIM (Onc), and Dr. Lee Helman, MD, to its Board of Directors. ... Chand and Lee as new directors. They will be of great help in advancing ...
Breaking Biology Technology:
Cached News: